Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning

Rhea-AI Summary

Philips (NYSE: PHG) received FDA 510(k) clearance on April 22, 2026 for its Rembra platform — Rembra CT, Rembra RT and Areta RT — enabling faster, higher-throughput CT imaging and integrated radiation therapy planning.

The platform features an 85 cm bore, next-generation 4DCT, an 85 cm extended field of view for treatment planning, and throughput claims up to 270 exams per day under test conditions.

Positive

• FDA 510(k) clearance for Rembra CT, Rembra RT, and Areta RT
• 85 cm bore design enabling larger field of view for therapy workflows
• Throughput claim of up to 270 exams/day supporting high-throughput settings
• 4DCT imaging and integrated CT-to-RT workflow for precise treatment planning

Negative

• EFOV not for diagnostics: 85 cm Extended Field of View is limited to treatment planning
• Throughput 270 exams/day is based on specific 16-hour testing and typical profiles
• EFOV performance validated versus phantom; clinical limits outside test conditions are not specified

News Market Reaction – PHG

-0.84%

-0.84% Session close to close

In the Apr 22 session, PHG declined 0.84%, reflecting a mild negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights FDA 510(k) clearance for Philips’ Rembra CT, Rembra RT, and Areta RT pl...

Analysis

This announcement highlights FDA 510(k) clearance for Philips’ Rembra CT, Rembra RT, and Areta RT platforms, enabling high-throughput imaging and precise radiation therapy planning with an 85 cm bore and capacity of up to 270 exams per day. It extends Philips’ CT presence across acute care and oncology workflows. In context of recent product clearances and innovation milestones, investors may watch for concrete adoption data, revenue contribution, and additional regulatory developments to gauge long-term impact.

Key Figures

CT bore size: 85 cm Daily exam capacity: 270 exams per day Extended field of view: 85 cm EFOV +5 more

8 metrics

CT bore size 85 cm Largest-in-class bore for Rembra CT front-line imaging

Daily exam capacity 270 exams per day Supported throughput for Rembra CT in demanding environments

Extended field of view 85 cm EFOV Field of view for radiation therapy planning (non-diagnostic)

Throughput test duration 16-hour day Basis for throughput testing of Rembra platform

Throughput test scans 203 patient scans / 12 hours Throughput testing figure for Rembra with typical protocols

Contour deviation Within 1 mm Mean Hausdorff distance external contour deviation in phantom test

Current share price $28.48 Price prior to market reaction on April 22, 2026

52-week range $21.95 – $33.435 52-week low and high before this news

Historical Context

5 past events · Latest: Apr 16 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 16	CT system clearance	Positive	-1.6%	FDA 510(k) clearance for AI-powered Spectral CT Verida system.
Apr 02	Governance/board update	Positive	-0.7%	Philips CMO appointed to MDIC Board of Directors.
Mar 26	AI cardiac clearance	Positive	-1.1%	FDA 510(k) clearance for EchoNavigator R5.0 with DeviceGuide.
Mar 25	Product launch	Positive	+2.7%	Launch of FDA 510(k)-cleared IntraSight Plus coronary intervention platform.
Mar 24	Innovation/patents	Positive	-0.3%	Recognition as No. 1 Medtech patent filer with significant R&D investment.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent Philips headlines are largely positive (product launches, FDA clearances, innovation accolades), yet four of the last five such events saw negative next-day price moves, indicating a tendency for the stock to trade lower even on favorable news.

Recent Company History

Over the past month, Philips reported several technology and regulatory milestones. On Mar 24, it highlighted leading Medtech patent activity and substantial R&D investment, followed on Mar 25 by the FDA‑cleared IntraSight Plus cardiology platform. Subsequent FDA 510(k) clearances for EchoNavigator DeviceGuide (Mar 26) and Spectral CT Verida (Apr 16) expanded its advanced imaging portfolio. A board appointment to MDIC on Apr 2 reinforced industry influence. Despite generally positive themes, price reactions were often modest or negative, similar to today’s clearance-driven news.

Key Terms

510(k) clearance, radiation therapy, 4dct imaging, extended field of view, +2 more

6 terms

510(k) clearance regulatory

"announced it has received 510(k) clearance from the U.S. Food and Drug Administration"

A 510(k) clearance is a U.S. regulatory approval that lets a medical device be sold because it is shown to be substantially similar to an already-legal device; think of it as a passport saying the new product is close enough to a known item to enter the market without a full, lengthy review. For investors, 510(k) clearance signals faster, lower-cost market access and reduced regulatory risk compared with new, untested device pathways, which can materially affect timelines, costs and revenue prospects.

radiation therapy medical

"demand for imaging and radiation therapy planning by helping to improve speed"

Radiation therapy uses focused high-energy rays or particles to kill or shrink abnormal cells inside the body, often delivered from outside the body or by placing tiny sources near the target. Think of it like using a magnifying glass to concentrate sunlight on a small spot to remove a weed without digging up the whole garden. Investors watch radiation therapy because its effectiveness, side effects, regulatory approvals, equipment needs and reimbursement rules directly affect healthcare companies’ revenues, clinical trial outcomes and long-term costs.

4dct imaging medical

"next generation 4DCT imaging capabilities, supporting more accurate targeting of tumors"

4DCT imaging is a form of computed tomography that captures a series of rapid CT scans over time to show moving anatomy — essentially a short video rather than a single snapshot — so clinicians can see how organs shift during breathing or heartbeat. Investors care because it improves the precision of diagnoses and treatments, influences demand for imaging hardware and software, and can affect regulatory approval, reimbursement and adoption of related medical devices and therapies.

extended field of view technical

"a wide 85 cm extended field of view [2] and next generation 4DCT imaging"

An extended field of view describes an imaging system’s ability to capture a wider area in a single image or scan than a standard device, similar to using a wide-angle lens instead of a narrow one. For investors, it matters because wider coverage can improve diagnostic or monitoring accuracy, reduce the need for repeat procedures, lower costs, and make products more competitive and attractive to customers and regulators.

hausdorff distance technical

"within 1 mm in terms of mean Hausdorff distance compared to the true external contour"

A Hausdorff distance is a mathematical measure of how far two shapes or sets are from each other, defined by the largest distance you have to travel from a point on one set to reach the other set. For investors, it’s used in quantitative analysis to compare entire price paths, scenarios, or model outputs—like checking whether a proposed trading strategy or risk model produces patterns that are acceptably close to historical behavior. Think of it as the worst-case gap between two outlines, useful for model validation and stress testing.

interventional settings medical

"various settings including emergency departments, critical care, and interventional settings"

Interventional settings are the medical places where doctors perform hands-on procedures using devices or instruments—for example operating rooms, catheterization labs, or procedure suites—rather than routine office visits or purely diagnostic tests. Investors care because products used in these settings often command higher prices, require regulatory clearance and training, and drive procedure volumes and hospital purchasing decisions, much like specialized tools sell differently than everyday household items.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

April 22, 2026

Clearances for Rembra CT, Rembra RT, and Areta RT enable high-throughput imaging at scale and elevate precision across the cancer care pathway

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Rembra platform of scanning systems, including Rembra CT, Rembra RT and Areta RT.

The newly cleared systems are designed to help healthcare providers respond to growing demand for imaging and radiation therapy planning by helping to improve speed, efficiency, and access to high-quality imaging. As imaging volumes and clinical complexity continue to rise, healthcare providers need solutions that can help them work more efficiently while maintaining confidence in clinical decisions.

The Rembra platform of systems also extends the role of CT across both diagnostic radiology and radiation therapy, helping to enable more connected workflows and a coordinated approach to patient care—from rapid assessment in acute settings to precise cancer treatment planning.

“As healthcare systems manage increasing demand and complexity, imaging plays a critical role in enabling timely and informed clinical decisions,” said Dan Xu, Business Leader of CT at Philips. “With the Rembra platform, we are redefining what clinicians can expect from CT, combining speed, scalability, and precision to expand access to high-quality imaging while supporting confident diagnosis and highly accurate treatment planning.”

With the largest-in-class 85 cm bore, Rembra CT is purpose-built for the front lines of care, enabling ultra-fast, high-throughput imaging in demanding clinical environments, supporting up to 270 exams per day [1] in various settings including emergency departments, critical care, and interventional settings. Its advanced acquisition and reconstruction capabilities support rapid, high-quality imaging at scale, helping clinicians make timely decisions in critical situations without compromising diagnostic confidence.

Rembra RT and Areta RT bring these performance advantages into radiation therapy, where precision is critical. These systems support high-fidelity imaging for treatment planning with a wide 85 cm extended field of view [2] and next generation 4DCT imaging capabilities, supporting more accurate targeting of tumors while helping protect healthy tissue. By streamlining simulation and planning workflows, they help reduce variability and improve efficiency, supporting more precise, personalized cancer care.

Together, the Rembra platform delivers a unified, high-performance CT ecosystem that spans the full care continuum—from urgent diagnosis to precision-guided therapy. It empowers healthcare providers to manage increasing demand with greater speed, consistency, and confidence while enabling more connected and efficient care delivery.

The FDA clearances further strengthen Philips’ comprehensive CT portfolio and reflect its continued focus on integrating advanced imaging technologies with intelligent and connected workflows. They also reflect Philips’ ongoing commitment to evolving its CT offering to address the changing needs of today’s imaging environments. By bringing together diagnostic and therapy solutions, Philips aims to support more efficient, coordinated care and improve the experience for both patients and care teams. 

[1] Based on a sixteen-hour day, with throughput testing with 203 patient scans/ 12 hours for Rembra with typical radiological profiles and protocols.
[2] The Extended Field of View (EFOV) of 85 cm is intended solely for use in treatment preparation and the planning/simulation of radiation therapy. It cannot be used for diagnostic purposes. The water equivalent material external contour deviation of body system phantom positioned (partially) outside scan FOV with phantom edge adjacent to bore cover is within 1 mm in terms of mean Hausdorff distance compared to the true external contour.


For further information, please contact:
Jayme Maniatis 
Philips Global External Relations  
Tel.: +1 617 804 8368
E-mail: jayme.maniatis@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.

Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2025 sales of EUR 18 billion and employs approximately 64,800 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips Rembra RT - image 1
• Philips Rembra RT - image 2
• Philips Areta RT - image 1
• Philips Areta RT - image 2

FAQ

What did Philips (PHG) announce on April 22, 2026 about Rembra FDA clearance?

Philips announced FDA 510(k) clearance for Rembra CT, Rembra RT and Areta RT on April 22, 2026. According to the company, the clearance covers a platform that enables higher-throughput CT and integrated radiation therapy planning with next-generation 4DCT capabilities.

How many exams per day can Rembra CT handle and what is the basis for that claim?

Rembra CT is claimed to support up to 270 exams per day under test conditions. According to the company, this figure is based on throughput testing that modeled 203 patient scans over 12 hours and a sixteen-hour operational day.

What does the 85 cm bore on Philips Rembra systems mean for clinical use (PHG)?

The 85 cm bore increases the extended field of view for treatment planning and larger patients. According to the company, the design supports therapy simulation and planning workflows but the EFOV is explicitly not intended for diagnostic imaging.

Does the Rembra platform include features for radiation therapy planning (PHG)?

Yes. Rembra RT and Areta RT include high-fidelity imaging, an 85 cm EFOV for planning, and next-generation 4DCT. According to the company, these features aim to improve targeting accuracy while protecting healthy tissue during treatment planning.

Can the Rembra EFOV be used for diagnostic CT exams for Philips (PHG)?

No. The 85 cm Extended Field of View is intended solely for radiation therapy treatment preparation and simulation. According to the company, EFOV cannot be used for diagnostic purposes and has specific validation limits described with phantom testing.

How might the FDA clearance for Rembra affect Philips' CT product lineup (PHG)?

The clearance broadens Philips' CT portfolio by integrating diagnostic and therapy-focused systems into one ecosystem. According to the company, Rembra strengthens connected workflows across urgent diagnosis and precision-guided cancer therapy, emphasizing speed and scalability.